It’s official. Consumer Reports’ engineers have just completed testing the iPhone 4, and have confirmed that there is a problem with its reception. When your finger or hand touches a spot on the phone’s lower left side—an easy thing, especially for lefties—the signal can significantly degrade enough to cause you to lose your connection altogether if you’re in an area with a weak signal. Due to this problem, we can’t recommend the iPhone 4.
That’s Consumer Reports, incidentally, which put the phone in an RF-isolated room to perform their tests along with a base-station emulator.
Oops – that’s about as close to proof as you’re going to find. In an RF-quiet environment it’s pretty easy to prove your case, and it appears that CR did so.
The tests also indicate that AT&T’s network might not be the primary suspect in the iPhone 4′s much-reported signal woes.
I have never been impressed with the iPhone (any generation) in terms of RF. Ever. It has always been a "form before function" device from my perspective, all the way back to the original units. Then again I’m spoiled – the best RF-performing GSM phone I’ve ever used was a Nokia 3395. I may still have one laying around here somewhere, and all of my old Nokias (including a 6610 which was nearly as good) still work just fine. Old, yes, but one thing Nokia does know how to do is design and build an RF section.
Incidentally, buying devices that work before selecting them for "sex appeal" may be why I’ve never had a material problem with the "can you hear me?" BS that so many suffer with when it comes to cellphones. I guess my view is that a cellphone is for communicating rather than trying to shag some hot chick at the local bar by flashing my "bling."
This is a common flaw for consumer devices – be sexy rather than be smart – or good. Of course sex sells, and so the more "sexy" you can make something look the better it sells, and as long as you remain within the "acceptable" functionality envelope you don’t get hurt – too badly. Witness Motorola, which had the "hot" phone for a long time…
Apple has had a hell of a time with what is arguably its most important product release since the initial iPhone in 2007. The handsets have been plagued with spotty screens, combustible USB ports, signal strength measurement inconsistencies, and the most damaging of the issues – an ill-conceived antenna design that causes attenuation when held from the lower left had corner. Steve Jobs did the Blankfein (Goldman Sachs CEO, stating that the Wall Street bank was doing God’s work) imitation by opening his mouth when he shouldn’t have and said that users were “hold the phone the wrong way”. Not only that, but Consumer Reports just came out with a report stating that they can not recommend the buying of an iPhone until the antenna situation has been rectified, prompting speculation that Apple will be forced to recall millions of phones.
As a matter of fact, the review was rather poignant:
“If you want an iPhone that works well without a masking-tape fix, we continue to recommend an older model, the 3G S.”
One solution to the Apple iPhone 4’s antenna problem is to cover the lower left corner with tape.
It is very easy to fall out of favor with the trendy crowd. While I doubt very seriously that Apple is in danger of doing this anytime soon, a massive recall will open the door for devices which are technically much more capable, flexible and open than the iPhone, ex. the Android powered HTC and Samsung devices. Basically, the danger to Apple here is not the expense of a recall, but the loss of mindshare and potential widening of the opening for some very capable competition – an opening that did not have to be there!
Don’t believe me, click the link to the consumer reports article and peruse the comment section…
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at firstname.lastname@example.org with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
Confused by what Janet Yellen said? As it turns out, so is everyone else, where the prevailing sentiment across the sell-side analysts was that Yellen was not dovish enough. Then again, with expectations bordering on Yellen giving the "BTFATH" green light, there is no way she was not going to disappoint...
First, and foremost, we start with the firm whose former employee runs the operational branch, i.e., the New York office, of the Fed, Goldman Sachs:
Goldman (Jan Hatzius):
We think the tone from Chair Yellen's Jackson Hole speech was broadly balanced, perhaps slightly more so than in past speeches.
The Weekly Leading Index (WLI) of the Economic Cycle Research Institute (ECRI) is at 134.3, unchanged from the previous week. The WLI annualized growth indicator (WLIg) dropped to 2.8 from the previous week's 3.5.
ECRI has been at the center of a prolonged controversy since publicizing its recession call on September 30, 2011. The company had made the announcement to its private clients on September 21st. ECRI's cofounder and spokesman, Lakshman Achuthan, subsequently forecast that the recession would begin in Q1 2012, or Q2 at the latest. He later identified mid-2012 as the start of the recession. Over the past two years he has been a frequent guest on the likes of CNBC and Bloomberg TV. In recent months he has adjust...
Is it time to short the dollar? Saxo bank chief economist Steen Jakobsen thinks so. Via email from Steen ... What is wrong with changing your mind because the facts changed? But you have to be able to say why you changed your mind and how the facts changed. Lee Iacocca
My biggest call all year has been for global lower rates, and in particular lower core country (Germany, Denmark, and US) yields led by this magic trinity of factors:
1. China and Asia rebalancing growth away from nominal to quality growth 2. US current account deficit reduced by 50% (see chart below) 3. A Europe where Germany will pay the price for the first two factors with a lag of six to nine months.
The headline call was and remains that Germany will be close to recession by Q4-2014 or Q1-2015 setting up a desperate ECB and a E...
Options volume on the provider of futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals and alternative investment products is well above average on Thursday morning, due in large part to a sizable put spread initiated in the 19Sep’14 expiry contracts. Shares in CME Group (Ticker: CME) are up slightly on the day, trading 0.25% higher at $74.34 as of the time of this writing.
The largest trade on CME today appears to be a bear put spread in which roughly 1,500 of the 19Sep’14 74.0 strike puts were purchased at a premium of $1.44 each against the sale of the same number of t...
As many investors enjoy the final weeks of summer, some optimistic bulls seem to be positioning themselves well ahead of Labor Day in anticipation of a fall rally. Indeed, last week’s action was impressive. After only a mere 4% correction, investors continued to brush off the disturbing violence both at home and abroad, and they took the minor pullback as their next buying opportunity. But was that really all the pullback we’re going to get this year? I doubt it. But I also believe that nothing short of a major Black Swan event can send this market into a deep correction.
In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, review our weekly fundamentals-based SectorCast rankings of the ten U.S. business sectors, and then ...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
Author Helen Davis Chaitman is a nationally recognized litigator with a diverse trial practice in the areas of lender liability, bankruptcy, bank fraud, RICO, professional malpractice, trusts and estates, and white collar defense. In 1995, Ms. Chaitman was named one of the nation's top ten litigators by the National Law Journal for a jury verdict she obtained in an accountants' malpractice case. Ms. Chaitman is the author of The Law of Lender Liability (Warren, Gorham & Lamont 1990)... Since early 2009, Ms. Chaitman has been an outspoken advocate for investors in Bernard L. Madoff Investment Securities LLC (more here).
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
I just wanted to be sure you saw this. There’s a ‘live’ training webinar this Thursday, March 27th at Noon or 9:00 pm ET.
If GOOGLE, the NSA, and Steve Jobs all got together in a room with the task of building a tremendously accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.
Well, I hate to break it to you though… they never got around to building it, but my friends at Market Tamer did.
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.